Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 10,400,000 shares, an increase of 9.2% from the August 15th total of 9,520,000 shares. Approximately 29.0% of the company’s shares are short sold. Based on an average daily trading volume, of 986,900 shares, the short-interest ratio is currently 10.5 days.
Intercept Pharmaceuticals Stock Performance
NASDAQ:ICPT traded down $0.27 during mid-day trading on Tuesday, hitting $11.06. The stock had a trading volume of 603,878 shares, compared to its average volume of 1,007,972. Intercept Pharmaceuticals has a 52 week low of $8.82 and a 52 week high of $21.86. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 3.31. The stock has a market capitalization of $462.09 million, a price-to-earnings ratio of 1.73 and a beta of 1.22. The company has a 50 day simple moving average of $10.80 and a 200-day simple moving average of $12.94.
Intercept Pharmaceuticals (NASDAQ:ICPT – Get Free Report) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.42. The firm had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $79.57 million. Intercept Pharmaceuticals had a net margin of 68.07% and a negative return on equity of 189.98%. Intercept Pharmaceuticals’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.68) earnings per share. On average, research analysts expect that Intercept Pharmaceuticals will post -1.06 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities analysts have weighed in on the stock. Bank of America decreased their price target on shares of Intercept Pharmaceuticals from $17.00 to $14.00 in a report on Tuesday, May 23rd. StockNews.com started coverage on shares of Intercept Pharmaceuticals in a report on Saturday, August 19th. They issued a “hold” rating on the stock. Canaccord Genuity Group increased their price objective on shares of Intercept Pharmaceuticals from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Royal Bank of Canada reduced their target price on shares of Intercept Pharmaceuticals from $14.00 to $13.00 in a report on Monday, June 26th. Finally, Needham & Company LLC downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intercept Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $22.36.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
- Five stocks we like better than Intercept Pharmaceuticals
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Invest in Solar Energy
- Virtual Riches: 3 Stocks Leading the VR Revolution
- 3 REITs to Buy and Hold for the Long Term
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.